TransMedics Group (TMDX) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $114.3 million, up 118% year-over-year, with net income of $12.2 million and positive free cash flow, driven by OCS product and transplant logistics expansion.

• Strategic focus on scaling aviation fleet, expanding transplant logistics, and launching new cardiothoracic clinical programs.

• Investments in infrastructure and pilot headcount are preparing for anticipated growth in 2025 and beyond.

• OCS platform remains the only FDA-approved, portable, multi-organ, warm perfusion technology for heart, lung, and liver transplants.

• Nearly all U.S. customers now participate in the National OCS Program (NOP).

Financial highlights

• Q2 2024 revenue reached $114.3 million, up 118% year-over-year and 18% sequentially; transplant-related revenue was $113.2 million.

• U.S. transplant revenue was $108.5 million, up 122% year-over-year; ex-U.S. revenue was $4.7 million, up 34%.

• Logistics service revenue grew to $19.1 million, a 32% increase quarter-over-quarter; service revenue for Q2 was $42.6 million.

• GAAP operating profit was $12.5 million (11% of revenue); net income was $12.2 million (10.7% margin); diluted EPS was $0.35.

• Cash balance at June 30, 2024, was $362.8 million; first positive free cash flow quarter generated $2 million.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $425–$445 million, representing 76%–84% growth over 2023.

• Guidance factors in scheduled aircraft maintenance and potential OUS revenue variability in H2 2024.

• Management expects continued profitability and positive operating profit, with some free cash flow variability due to ongoing investments.

• Expects continued revenue growth from NOP expansion and increased OCS adoption in U.S. and select international markets.

• Existing cash expected to fund operations, capex, and debt service for at least 12 months.